Inhibrx Biosciences, Inc. Operating Income Loss

Quick Answer

Inhibrx Biosciences, Inc. reported Operating Income Loss of -$135.03 million for the year ending 2025.

  • Inhibrx Biosciences, Inc. showed an increase of +59.3% in Operating Income Loss from 2024 to 2025.
  • This data is from Inhibrx Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
  • XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 3 years of available data (2023 to 2025), Inhibrx Biosciences, Inc.'s Operating Income Loss has grown by 38.4%.
  • Historical annual values: Fiscal year 2025: -$135.03 million | Fiscal year 2024: -$331.45 million | Fiscal year 2023: -$219.22 million.
  • Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: